Meldex is pleased to announce the signing of a sales and distribution agreement with Al-Mawarid Drug Store for the Menoflavon® range of products in Jordan.

The Closing Date for the Minimum Subscription under the revised terms of the Secured Loan Note offer is 11 September 2009. The directors intend that applications made after 11 September will be at a higher conversion price.

MORE >

NRobe™

NRobe™ tablets

Overview

NRobe™: a unique and revolutionary solid oral dose

NRobe™ provides a new solid oral dose form to the pharmaceutical industry. The technology consists of a process, equipment and film to produce NRobe™ dosage forms.

The active pharmaceutical ingredient and excipients are lightly compressed, enrobed between two films, and sealed to provide a compacted, coated dosage form. FMC Magenta is the exclusive, worldwide licensee of NRobe™ technology from Meldex and is responsible for the commercialisation and continuing development of the technology.

Features of NRobe™:

elegant presentation of compression sensitive or moisture sensitive formulations
improved dissolution versus conventional oral dosage forms
reduced dependence on problematic excipients
reduced formulation time
improved manufacturing efficiencies with an “all-in-one” process

For further information please follow this link:

http://www.fmcmagenta.com/NRobe/tabid/145/Default.aspx